

Matthew T Chang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10586972/publications.pdf>

Version: 2024-02-01

30
papers

9,508
citations

236925

25
h-index

434195

31
g-index

31
all docs

31
docs citations

31
times ranked

17626
citing authors

#	ARTICLE	IF	CITATIONS
1	AKT mutant allele-specific activation dictates pharmacologic sensitivities. <i>Nature Communications</i> , 2022, 13, 2111.	12.8	10
2	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 447-459.	7.0	22
3	Combined Inhibition of G1±q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 1476-1490.	7.0	29
4	Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways. <i>Cancer Discovery</i> , 2021, 11, 778-793.	9.4	26
5	The Hippo Pathway as a Driver of Select Human Cancers. <i>Trends in Cancer</i> , 2020, 6, 781-796.	7.4	39
6	An integrated molecular profile of endometrioid ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 55-61.	1.4	43
7	Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. <i>Cancer Research</i> , 2020, 80, 4233-4243.	0.9	18
8	Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis. <i>Cancer Discovery</i> , 2019, 9, 1452-1467.	9.4	60
9	Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K± inhibitors. <i>Science</i> , 2019, 366, 714-723.	12.6	185
10	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. <i>Cancer Discovery</i> , 2018, 8, 648-661.	9.4	97
11	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018, 8, 174-183.	9.4	275
12	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. <i>Clinical Cancer Research</i> , 2018, 24, 1965-1973.	7.0	85
13	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. <i>Cancer Cell</i> , 2018, 34, 852-862.e4.	16.8	73
14	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	16.8	633
15	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5939-5947.	7.0	100
16	Genome doubling shapes the evolution and prognosis of advanced cancers. <i>Nature Genetics</i> , 2018, 50, 1189-1195.	21.4	411
17	3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. <i>Genome Medicine</i> , 2017, 9, 4.	8.2	170
18	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473

#	ARTICLE	IF	CITATIONS
19	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	9.4	490
20	USP7 small-molecule inhibitors interfere with ubiquitin binding. <i>Nature</i> , 2017, 550, 534-538.	27.8	258
21	Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 735-748.	27.6	234
22	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. <i>Nature</i> , 2017, 548, 234-238.	27.8	394
23	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , 2017, 32, 204-220.e15.	16.8	642
24	AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259.	1.6	240
25	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
26	Recurrent activating mutations of G-protein-coupled receptor <i>CYSLTR2</i> in uveal melanoma. <i>Nature Genetics</i> , 2016, 48, 675-680.	21.4	236
27	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. <i>Nature Biotechnology</i> , 2016, 34, 155-163.	17.5	634
28	Clinical Sequencing Contributes to aBRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 835-845.	4.9	3
29	Clinical application of pharmacogenetics: focusing on practical issues. <i>Pharmacogenomics</i> , 2015, 16, 1733-1741.	1.3	14
30	Copy number alteration burden predicts prostate cancer relapse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11139-11144.	7.1	299